ROSIGLITAZONE THRPY FOR PREV OF COR ARTERY DISEASE IN PTS W/IMPAIRD GLUCOSE TOL

罗格列酮苏吡酮用于预防葡萄糖耐受不良患者的冠状动脉疾病

• 批准号: 7377800
• 负责人: JANE E REUSCH
• 金额: $ 1.11万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377800
• 关键词: ROSIGLITAZONE; THRPY; PREV; COR; ARTERY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an 18-month study looking at prevention of coronary artery disease progression in people with impaired glucose tolerance on rosiglitazone vs. placebo.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项为期18个月的研究，旨在观察罗格列酮与安慰剂对糖耐量受损患者冠状动脉疾病进展的预防作用。